AGP Picks
View all

Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on August 27, 2026

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GRI Bio Featured in "Why Now" On-Demand Video Webcast
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
L’étude Can-RISE nationale aide à combler les lacunes en recherche sur la ménopause
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Power to Decide Announces Lori Adelman as Chief Executive Officer
Verizon anuncia una enorme toma de la NFL en Verizon Shine: miles de boletos por nuestra cuenta para partidos de la NFL y regalos, además de más de 20 experiencias VIP épicas de fútbol americano solo para clientes de Verizon
CalciMedica Announces One-for-Five Reverse Stock Split
Codexis to Participate in Cantor Global Healthcare Conference 2026
Verizon announces massive NFL takeover in Verizon Shine: Thousands of free tickets to NFL games and giveaways, plus 20+ epic VIP football experiences just for Verizon customers
argenx Completes Acquisition of Forte Biosciences, Inc.
The International Myeloma Foundation Wants You to #KnowMyeloma for Blood Cancer Awareness Month 2026
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ICU Medical to Participate in Upcoming Investor Conferences
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Alternative Medicine Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.